文献速递肾小球疾病

COVID-19与疫苗接种对原发性肾小球疾病肾功能及疾病活动度的影响

Association of COVID-19 Versus COVID-19 Vaccination With Kidney Function and Disease Activity in Primary Glomerular Disease: A Report of the Cure Glomerulonephropathy Study.
PubMed 文献 · Am J Kidney Dis · 2023-08-31

基于CureGN前瞻性观察网络71中心2055例原发性肾小球疾病患者,2021年7月至2023年1月观察。COVID-19感染与随后蛋白尿定义的疾病活动度恶化风险升高相关(HR 1.35,95%CI 1.01-1.80),而疫苗接种未与eGFR变化或疾病恶化相关。

要点

  • COVID-19感染后肾小球疾病活动度恶化风险升高(HR 1.35,95%CI 1.01-1.80)。
  • 疫苗接种未与eGFR变化(P=0.6)或疾病恶化(HR 1.02,95%CI 0.79-1.33)相关。
  • 2055例中722例(35%)报告COVID-19感染,其中92例(13%)住院,3例死亡(<1%)。

核心结论

  • 在原发性肾小球疾病患者中,COVID-19感染与随后蛋白尿定义的疾病活动度恶化相关,而疫苗接种未与疾病活动度变化或肾功能下降相关。

研究设计与样本

  • 来自北美和欧洲71个中心的前瞻性观察研究网络(CureGN)的观察性队列研究,纳入儿童和成人原发性微小病变、局灶节段性肾小球硬化、膜性肾病或IgA肾病患者,时间2021年7月1日至2023年1月1日。

主要发现

  • 2055例参与者中722例(35%)报告COVID-19感染,其中92例(13%)住院,3例死亡(<1%)。
  • COVID-19感染前eGFR斜率为-1.40mL/min/1.73m2(±0.29 SD);感染后6个月内eGFR斜率为-4.26mL/min/1.73m2(±3.02 SD),差异无统计学意义(P=0.34)。
  • COVID-19与肾小球疾病活动度恶化风险升高相关(HR 1.35,95%CI 1.01-1.80)。
  • 疫苗接种与eGFR变化无关(-1.34mL/min/1.73m2±0.15 SD vs -2.16mL/min/1.73m2±1.74 SD;P=0.6)。
  • 疫苗接种与随后肾小球疾病恶化无关(HR 1.02,95%CI 0.79-1.33)。

关键数值与推荐

  • 肾小球疾病恶化定义为尿蛋白肌酐比值(UPCR)倍增且至少达1.5g/g,或尿试纸蛋白增加2个等级至3+(300mg/dL)或以上。

临床怎么用

  • 结果支持为肾小球疾病患者接种COVID-19疫苗。

局限性

  • 随访不频繁或时间短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Patients with glomerular disease (GN) may be at increased risk of severe COVID-19, yet concerns over vaccines causing disease relapse may lead to vaccine hesitancy. We examined the associations of COVID-19 with longitudinal kidney function and proteinuria and compared these with similar associations with COVID-19 vaccination. STUDY DESIGN: Observational cohort study from July 1, 2021, to January 1, 2023. SETTING & PARTICIPANTS: A prospective observational study network of 71 centers from North America and Europe (CureGN) with children and adults with primary minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, or IgA nephropathy. EXPOSURE: COVID-19 and COVID-19 vaccination. OUTCOME: Repeated measure of estimated glomerular filtration rate (eGFR); recurrent time-to-event outcome of GN disease worsening as defined by doubling of the urinary protein-creatinine ratio (UPCR) to at least 1.5g/g or increase in dipstick urine protein by 2 ordinal levels to 3+(300mg/dL) or above. ANALYTICAL APPROACH: Interrupted time series analysis for eGFR. Prognostic matched sequential stratification recurrent event analysis for GN disease worsening. RESULTS: Among 2,055 participants, 722 (35%) reported COVID-19 infection; of these, 92 (13%) were hospitalized, and 3 died (<1%). The eGFR slope before COVID-19 infection was-1.40mL/min/1.73m2 (± 0.29 SD); within 6 months after COVID-19 infection, the eGFR slope was-4.26mL/min/1.73m2 (± 3.02 SD), which was not significantly different (P=0.34). COVID-19 was associated with increased risk of worsening GN disease activity (HR, 1.35 [95% CI, 1.01-1.80]). Vaccination was not associated with a change in eGFR (-1.34mL/min/1.73m2±0.15 SD vs-2.16mL/min/1.73m2±1.74 SD; P=0.6) or subsequent GN disease worsening (HR 1.02 [95% CI, 0.79-1.33]) in this cohort. LIMITATIONS: Infrequent or short follow-up. CONCLUSIONS: Among patients with primary GN, COVID-19 infection was severe for 1 in 8 cases and was associated with subsequent worsening of GN disease activity, as defined by proteinuria. By contrast, vaccination against COVID-19 was not associated with change in disease activity or kidney function decline. These results support COVID-19 vaccination for patients with GN. PLAIN-LANGUAGE SUMMARY: In this cohort study of 2,055 patients with minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, or IgA nephropathy, COVID-19 resulted in hospitalization or death for 1 in 8 cases and was associated with a 35% increase in risk for worsening proteinuria. By contrast, vaccination did not appear to adversely affect kidney function or proteinuria. Our data support vaccination for COVID-19 in patients with glomerular disease.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Wang CS, Glenn DA, Helmuth M, et al. Association of COVID-19 Versus COVID-19 Vaccination With Kidney Function and Disease Activity in Primary Glomerular Disease: A Report of the Cure Glomerulonephropathy Study. Am J Kidney Dis. 2023. PMID: 37657635. doi:10.1053/j.ajkd.2023.07.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。